About this trial

Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.

Eligibility criteria

Qualifiers

Moderate-severe CKD determined by eGFR <50ml/min per 1.73m2 by CKD EPI equation on at least 2 consecutive occasions.

Metabolic acidosis defined as bicarbonate level<24 on two consecutive occasions. Bicarbonate level of 24 or less allowed if eGFR<=45ml/min per 1.73m2

Age 21 to 85 years old

Disqualifiers

Type 1 diabetes

Poorly controlled diabetes (HgbA1c>10%)

History of persistent hyperkalemia (K>5.4)

History of persistent hypokalemia (K<3.3)

Trial design

Treatments tested in this trial

  • Sodium bicarbonate
  • placebo

Treatment groups

80 Participants
are divided into 2 treatment groups

Locations

2
University of California Davis Health95817, SacramentoCalifornia, United States
Vanderbilt University Medical Center37232, NashvilleTennessee, United States

Sponsors and collaborators

University of California, Davis

Lead sponsor

Vanderbilt University Medical Center

Collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator